DRUG major Cipla on Friday announced the launch of its proprietary respiratory inhalation therapy product 'Niveoli' in India. Niveoli is used in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD), Cipla said in a BSE filing. Cipla said Niveoli, extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targets drug delivery to the small airways.
